Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341-54
   PubMed Web of Science ®Google Scholar
• Hanna N, Lilenbaum R, Ansari R, Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24(33):5253-8
   Google Scholar
• Burtness B, Goldwasser MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54
   PubMed Web of Science ®Google Scholar
• Raben D, Helfrich B, Chan DC, The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11(2 Pt 1):795-805
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290(16):2149-58
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237-46
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-11
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98(12):1817-24
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23(4):857-65
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97(5):339-46
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305(5687):1163-7
   PubMed Web of Science ®Google Scholar
• Tracy S, Mukohara T, Hansen M, Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64(20):7241-4
   PubMed Web of Science ®Google Scholar
• Han SW, Kim TY, Hwang PG, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23(11):2493-501
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97(9):643-55
   PubMed Web of Science ®Google Scholar
• Cortes-Funes H, Gomez C, Rosell R, Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005;16(7):1081-6
   Google Scholar
• Taron M, Ichinose Y, Rosell R, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11(16):5878-85
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Sakamoto H, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(28):6829-37
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44
   PubMed Web of Science ®Google Scholar
• Tomizawa Y, Iijima H, Sunaga N, Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005;11(19 Pt 1):6816-22
   Google Scholar
• Hirsch FR, Varella-Garcia M, McCoy J, Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23(28):6838-45
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005;29(5):633-9
   Google Scholar
• Riely GJ, Pao W, Pham D, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-44
   PubMed Web of Science ®Google Scholar
• Takano T, Fukui T, Ohe Y, EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26(34):5589-95
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Cappuzzo F, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18(4):752-60
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24(31):5034-42
   PubMed Web of Science ®Google Scholar
• Kaye FJ. A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity? J Natl Cancer Inst 2005;97(9):621-3
   Google Scholar
• Amann J, Kalyankrishna S, Massion PP, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65(1):226-35
   Web of Science ®Google Scholar
• Dongiovanni D, Daniele L, Barone C, Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung cancer 2008;61(1):73-81
   PubMed Web of Science ®Google Scholar
• Slebos RJ, Kibbelaar RE, Dalesio O, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323(9):561-5
   PubMed Web of Science ®Google Scholar
• Ahrendt SA, Decker PA, Alawi EA, Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92(6):1525-30
   PubMed Web of Science ®Google Scholar
• Tam IY, Chung LP, Suen WS, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12(5):1647-53
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2(1):e17
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Endoh H, Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64(24):8919-23
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23(25):5900-9
   PubMed Web of Science ®Google Scholar
• Uchida A, Hirano S, Kitao H, Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 2007;98(3):357-63
   Google Scholar
• Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 2007;6(6):1765-73
   PubMed Web of Science ®Google Scholar
• Riely GJ, Johnson ML, Medina C, A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 2011;6(8):1435-7
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65(5):1642-6
   PubMed Web of Science ®Google Scholar
• Sasaki H, Shimizu S, Endo K, EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006;118(1):180-4
   PubMed Web of Science ®Google Scholar
• Daniele L, Macri L, Schena M, Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 2007;6(4):1223-9
   Google Scholar
• Cappuzzo F, Varella-Garcia M, Shigematsu H, Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23(22):5007-18
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10(1):25-38
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354(24):2619-21
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ligorio C, Toschi L, EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(5):423-9
   Google Scholar
• Hennessy BT, Smith DL, Ram PT, Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4(12):988-1004
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA, Mermel C, ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005;102(10):3788-93
   PubMed Web of Science ®Google Scholar
• Erjala K, Sundvall M, Junttila TT, Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12(13):4103-11
   PubMed Web of Science ®Google Scholar
• Piechocki MP, Yoo GH, Dibbley SK, Lonardo F. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res 2007;67(14):6825-43
   Google Scholar
• Soung YH, Lee JW, Kim SY, Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006;118(6):1426-9
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455(7216):1069-75
   PubMed Web of Science ®Google Scholar
• Tvorogov D, Sundvall M, Kurppa K, Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 2009;284(9):5582-91
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22(14):2954-63
   PubMed Web of Science ®Google Scholar
• Noro R, Gemma A, Miyanaga A, PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 2007;31(5):1157-63
   PubMed Web of Science ®Google Scholar
• Lee SY, Hur GY, Jung KH, PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 2006;51(3):297-301
   Google Scholar
• Kokubo Y, Gemma A, Noro R, Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005;92(9):1711-19
   PubMed Web of Science ®Google Scholar
• Chin TM, Quinlan MP, Singh A, Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res 2008;14(21):6867-76
   PubMed Web of Science ®Google Scholar
• She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res 2003;9(12):4340-6
   PubMed Web of Science ®Google Scholar
• Bianco R, Shin I, Ritter CA, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22(18):2812-22
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Johansen MJ, Zhang D, Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007;67(12):5779-88
   PubMed Web of Science ®Google Scholar
• Markman B, Atzori F, Perez-Garcia J, Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010;21(4):683-91
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352(8):786-92
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2(3):e73
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102(21):7665-70
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105(6):2070-5
   PubMed Web of Science ®Google Scholar
• Carter TA, Wodicka LM, Shah NP, Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102(31):11011-16
   PubMed Web of Science ®Google Scholar
• Azam M, Seeliger MA, Gray NS, Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008;15(10):1109-18
   PubMed Web of Science ®Google Scholar
• Inukai M, Toyooka S, Ito S, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66(16):7854-8
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100(3):1014-18
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Komor M, Wassmann B, Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003;102(2):659-61
   Google Scholar
• Vikis H, Sato M, James M, EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007;67(10):4665-70
   Google Scholar
• Mulloy R, Ferrand A, Kim Y, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67(5):2325-30
   PubMed Web of Science ®Google Scholar
• Godin-Heymann N, Bryant I, Rivera MN, Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007;67(15):7319-26
   PubMed Web of Science ®Google Scholar
• Greulich H, Chen TH, Feng W, Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2(11):e313
   PubMed Web of Science ®Google Scholar
• Balak MN, Gong Y, Riely GJ, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12(21):6494-501
   PubMed Web of Science ®Google Scholar
• Sasaki H, Endo K, Takada M, EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007;58(3):324-8
   Google Scholar
• Costa DB, Halmos B, Kumar A, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4(10):1669-79; discussion 80
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-43
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104(52):20932-7
   PubMed Web of Science ®Google Scholar
• Okuda K, Sasaki H, Yukiue H, Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99(11):2280-5
   PubMed Web of Science ®Google Scholar
• Onozato R, Kosaka T, Kuwano H, Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009;4(1):5-11
   PubMed Web of Science ®Google Scholar
• Kubo T, Yamamoto H, Lockwood WW, MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009;124(8):1778-84
   PubMed Web of Science ®Google Scholar
• Yano S, Wang W, Li Q, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68(22):9479-87
   PubMed Web of Science ®Google Scholar
• Wang W, Li Q, Yamada T, Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009;15(21):6630-8
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17(1):77-88
   PubMed Web of Science ®Google Scholar
• Onitsuka T, Uramoto H, Nose N, Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010;68(2):198-203
   PubMed Web of Science ®Google Scholar
• Sharma SV, Lee DY, Li B, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141(1):69-80
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118(7):2609-19
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Discafani CM, Rosfjord EC, Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64(11):3958-65
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28(18):3076-83
   PubMed Web of Science ®Google Scholar
• Wong KK, Fracasso PM, Bukowski RM, A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15(7):2552-8
   PubMed Web of Science ®Google Scholar
• Ji H, Li D, Chen L, The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006;9(6):485-95
   Google Scholar
• Eskens FA, Mom CH, Planting AS, A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008;98(1):80-5
   PubMed Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28(25):3965-72
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• Yamada T, Matsumoto K, Wang W, Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010;16(1):174-83
   PubMed Web of Science ®Google Scholar
• Moreira-Leite FF, Harrison LR, Mironov A, Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy. J Thorac Oncol 2010;5(6):765-77
   PubMed Web of Science ®Google Scholar
• Ghosh G, Lian X, Kron SJ, Palecek SP. Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer 2012;12(1):95
   Google Scholar
• Dong H, Wang S. Exploring the cancer genome in the era of next-generation sequencing. Front Med 2012;6(1):48-55
   PubMedGoogle Scholar